Q1 Earnings Estimate for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a report issued on Monday, March 17th. Leerink Partnrs analyst F. Khurshid expects that the company will earn ($0.89) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q2 2025 earnings at ($0.93) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%.

Several other analysts have also weighed in on NRIX. BMO Capital Markets assumed coverage on Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Royal Bank of Canada upped their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Leerink Partners assumed coverage on Nurix Therapeutics in a report on Monday. They issued a “market perform” rating and a $16.00 price objective for the company. Stifel Nicolaus upped their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. reduced their target price on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.88.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $13.87 on Wednesday. Nurix Therapeutics has a 1 year low of $11.90 and a 1 year high of $29.56. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.80 and a beta of 2.18. The business has a fifty day moving average of $17.10 and a 200-day moving average of $20.88.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 over the last 90 days. 7.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Nurix Therapeutics

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of Nurix Therapeutics by 85.2% in the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock valued at $1,531,000 after purchasing an additional 31,352 shares during the last quarter. Barclays PLC grew its position in shares of Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company’s stock valued at $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. FMR LLC grew its position in shares of Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after purchasing an additional 511,256 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Nurix Therapeutics in the third quarter valued at approximately $530,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.